<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01118325</url>
  </required_header>
  <id_info>
    <org_study_id>D5130C00065</org_study_id>
    <nct_id>NCT01118325</nct_id>
  </id_info>
  <brief_title>An Asian Study to Assess the Properties and Profile of Ticagrelor in Patients With Stable Coronary Artery Disease</brief_title>
  <official_title>A Randomised, Double-Blind, Parallel Group, Asian, Multicenter Study, to Assess Pharmacokinetic and Pharmacodynamic Profile of 2 Doses of Ticagrelor on Top of Low Dose Acetyl Salicylic Acid (ASA) Therapy on Platelet Aggregation in Japanese and Asian Patients With Stable Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the drug characteristics of Ticagrelor, and to
      determine if 4 weeks treatment will reduce the blood clotting.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Inhibition of Platelet Aggregation(IPA) Final Extent at 2 Hours Post Dose on Week 4 in Japanese Patients</measure>
    <time_frame>Week 4</time_frame>
    <description>Final extent IPA from pre-dose baseline was calculated using the following formula for Adenosine Diphosphate (ADP)-induced platelet aggregation:
Percentage Inhibition = 100% x (PAs - PA) / (PAs) Platelet Aggregation (PA) was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval [0,100]; any data falling outside this range was truncated to the appropriate limit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IPA Final Extent at 4 Hours Post Dose on Week 4 in Japanese Patients</measure>
    <time_frame>Week 4</time_frame>
    <description>Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation:
Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval [0,100]; any data falling outside this range was truncated to the appropriate limit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IPA Final Extent at 8 Hours Post Dose on Week 4 in Japanese Patients</measure>
    <time_frame>Week 4</time_frame>
    <description>Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation:
Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval [0,100]; any data falling outside this range was truncated to the appropriate limit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IPA Final Extent at 12 Hours Post Dose on Week 4 in Japanese Patients</measure>
    <time_frame>Week 4</time_frame>
    <description>Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation:
Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval [0,100]; any data falling outside this range was truncated to the appropriate limit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IPA Final Extent at 24 Hours Post Dose on Week 4 in Japanese Patients</measure>
    <time_frame>Week 4</time_frame>
    <description>Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation:
Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval [0,100]; any data falling outside this range was truncated to the appropriate limit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AZD6140 (Cmax) at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Maximum plasma AZD6140 concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AZD6140 (AUC0-tau) at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Area under the plasma concentration curve of AZD6140 from time zero to dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AZD6140 (Tmax) at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Time to reach peak or maximum concentration of AZD6140 following AZD6140 administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AR-C124910XX (Cmax) at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Maximum plasma concentration of AZD6140 drug metabolite AR-C124910XX</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AR-C124910XX (AUC0-tau) at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Area under the plasma concentration curve of AZD6140 drug metabolite AR-C124910XX from time zero to dosing interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AR-C124910XX (Tmax) at Week 4</measure>
    <time_frame>Week 4</time_frame>
    <description>Time to reach peak or maximum concentration of AZD6140 drug metabolite AR-C124910XX following AZD6140 administration</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">146</enrollment>
  <condition>Stable Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>AZD6140 45 mg bd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD6140 90 mg bd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel 75 mg od</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ticagrelor</intervention_name>
    <description>Drug oral treatment</description>
    <arm_group_label>AZD6140 45 mg bd</arm_group_label>
    <arm_group_label>AZD6140 90 mg bd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel</intervention_name>
    <description>Drug oral treatment</description>
    <arm_group_label>Clopidogrel 75 mg od</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any Percutaneous Coronary Intervention, more than 3 months prior to randomization

          -  Previous documented acute coronary syndrome (ACS), more than 3 months prior to
             randomisation

          -  Treatment with ASA

        Exclusion Criteria:

          -  ACS, transient ischemic attack (TIA), or Stroke within the 3 months prior to
             randomisation

          -  Known concurrent disease of stroke or TIA with atrial fibrillation

          -  Persons who are being treated with blood clotting agents that cannot be stopped
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan C. Fox, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mizumaki</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toride-shi</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kawasaki-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyoto-shi</city>
        <state>Kyoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Naha-shi</city>
        <state>Okinawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kusatsu-shi</city>
        <state>Shiga</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Komatsushima-shi</city>
        <state>Tokushima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Davao City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quezon City</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Philippines</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=374&amp;filename=CSR-D5130C00065.pdf</url>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&amp;studyid=374&amp;filename=CSR-D5130C00065.pdf</url>
    <description>CSR-D5130C00065.pdf</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=374&amp;filename=D5130C00065_CSP_Redacted_17_Oct_2013.pdf</url>
    <description>D5130C00065_CSP_redacted_17_Oct_2013</description>
  </link>
  <reference>
    <citation>Hiasa Y, Teng R, Emanuelsson H. Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary artery disease. Cardiovasc Interv Ther. 2014 Oct;29(4):324-33. doi: 10.1007/s12928-014-0277-1. Epub 2014 Jun 17.</citation>
    <PMID>24935072</PMID>
  </reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2010</study_first_submitted>
  <study_first_submitted_qc>May 5, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2010</study_first_posted>
  <results_first_submitted>March 14, 2012</results_first_submitted>
  <results_first_submitted_qc>March 14, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 9, 2012</results_first_posted>
  <disposition_first_submitted>February 23, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>June 1, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 7, 2011</disposition_first_posted>
  <last_update_submitted>June 24, 2014</last_update_submitted>
  <last_update_submitted_qc>June 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stable Coronary Artery Disease</keyword>
  <keyword>Platelet Aggregation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>In total, 146 patients were enrolled at 15 sites from 2 countries (Japan and Philippines). The study period was from April 2010 to March 2011. In total, 139 subjects were randomised and received the investigational product. Most subjects completed the study but 2 Japanese patients discontinued due to an AE during the 4 weeks treatment period.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>AZD6140 45 mg bd</title>
          <description>AZD6140 45 mg twice daily</description>
        </group>
        <group group_id="P2">
          <title>AZD6140 90 mg bd</title>
          <description>AZD6140 90 mg twice daily</description>
        </group>
        <group group_id="P3">
          <title>Clopidogrel 75 mg od</title>
          <description>Clopidogrel 75 mg once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AZD6140 45 mg bd</title>
          <description>AZD6140 45 mg twice daily</description>
        </group>
        <group group_id="B2">
          <title>AZD6140 90 mg bd</title>
          <description>AZD6140 90 mg twice daily</description>
        </group>
        <group group_id="B3">
          <title>Clopidogrel 75 mg od</title>
          <description>Clopidogrel 75 mg once daily</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="46"/>
            <count group_id="B4" value="139"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="11"/>
                    <measurement group_id="B2" value="64" spread="9"/>
                    <measurement group_id="B3" value="64" spread="10"/>
                    <measurement group_id="B4" value="63" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Inhibition of Platelet Aggregation(IPA) Final Extent at 2 Hours Post Dose on Week 4 in Japanese Patients</title>
        <description>Final extent IPA from pre-dose baseline was calculated using the following formula for Adenosine Diphosphate (ADP)-induced platelet aggregation:
Percentage Inhibition = 100% x (PAs - PA) / (PAs) Platelet Aggregation (PA) was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval [0,100]; any data falling outside this range was truncated to the appropriate limit.</description>
        <time_frame>Week 4</time_frame>
        <population>Only Japanese participants who had IPA data at Week 4 were considered in this analysis. Arm AZD6140 90 mg bd includes one non-Japanese participant resident in Japan</population>
        <group_list>
          <group group_id="O1">
            <title>AZD6140 45 mg bd</title>
            <description>AZD6140 45 mg twice daily in Japanese patients</description>
          </group>
          <group group_id="O2">
            <title>AZD6140 90 mg bd</title>
            <description>AZD6140 90 mg twice daily in Japanese patients</description>
          </group>
          <group group_id="O3">
            <title>Clopidogrel 75 mg od</title>
            <description>Clopidogrel 75 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Inhibition of Platelet Aggregation(IPA) Final Extent at 2 Hours Post Dose on Week 4 in Japanese Patients</title>
          <description>Final extent IPA from pre-dose baseline was calculated using the following formula for Adenosine Diphosphate (ADP)-induced platelet aggregation:
Percentage Inhibition = 100% x (PAs - PA) / (PAs) Platelet Aggregation (PA) was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval [0,100]; any data falling outside this range was truncated to the appropriate limit.</description>
          <population>Only Japanese participants who had IPA data at Week 4 were considered in this analysis. Arm AZD6140 90 mg bd includes one non-Japanese participant resident in Japan</population>
          <units>percentage inhibition</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.5" spread="14.8"/>
                    <measurement group_id="O2" value="73.0" spread="14.2"/>
                    <measurement group_id="O3" value="38.9" spread="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>IPA Final Extent at 4 Hours Post Dose on Week 4 in Japanese Patients</title>
        <description>Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation:
Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval [0,100]; any data falling outside this range was truncated to the appropriate limit.</description>
        <time_frame>Week 4</time_frame>
        <population>Only Japanese participants who had IPA data at Week 4 were considered in this analysis. Arm AZD6140 90 mg bd includes one non-Japanese participant resident in Japan</population>
        <group_list>
          <group group_id="O1">
            <title>AZD6140 45 mg bd</title>
            <description>AZD6140 45 mg twice daily in Japanese patients</description>
          </group>
          <group group_id="O2">
            <title>AZD6140 90 mg bd</title>
            <description>AZD6140 90 mg twice daily in Japanese patients</description>
          </group>
          <group group_id="O3">
            <title>Clopidogrel 75 mg od</title>
            <description>Clopidogrel 75 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>IPA Final Extent at 4 Hours Post Dose on Week 4 in Japanese Patients</title>
          <description>Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation:
Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval [0,100]; any data falling outside this range was truncated to the appropriate limit.</description>
          <population>Only Japanese participants who had IPA data at Week 4 were considered in this analysis. Arm AZD6140 90 mg bd includes one non-Japanese participant resident in Japan</population>
          <units>percentage inhibition</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.3" spread="15.6"/>
                    <measurement group_id="O2" value="73.2" spread="15.1"/>
                    <measurement group_id="O3" value="43.7" spread="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>IPA Final Extent at 8 Hours Post Dose on Week 4 in Japanese Patients</title>
        <description>Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation:
Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval [0,100]; any data falling outside this range was truncated to the appropriate limit.</description>
        <time_frame>Week 4</time_frame>
        <population>Only Japanese participants who had IPA data at Week 4 were considered in this analysis. Arm AZD6140 90 mg bd includes one non-Japanese participant resident in Japan</population>
        <group_list>
          <group group_id="O1">
            <title>AZD6140 45 mg bd</title>
            <description>AZD6140 45 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>AZD6140 90 mg bd</title>
            <description>AZD6140 90 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Clopidogrel 75 mg od</title>
            <description>Clopidogrel 75 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>IPA Final Extent at 8 Hours Post Dose on Week 4 in Japanese Patients</title>
          <description>Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation:
Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval [0,100]; any data falling outside this range was truncated to the appropriate limit.</description>
          <population>Only Japanese participants who had IPA data at Week 4 were considered in this analysis. Arm AZD6140 90 mg bd includes one non-Japanese participant resident in Japan</population>
          <units>percentage inhibition</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.7" spread="17.7"/>
                    <measurement group_id="O2" value="68.6" spread="16.0"/>
                    <measurement group_id="O3" value="42.5" spread="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>IPA Final Extent at 12 Hours Post Dose on Week 4 in Japanese Patients</title>
        <description>Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation:
Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval [0,100]; any data falling outside this range was truncated to the appropriate limit.</description>
        <time_frame>Week 4</time_frame>
        <population>Only Japanese participants who had IPA data at Week 4 were considered in this analysis. Arm AZD6140 90 mg bd includes one non-Japanese participant resident in Japan</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1 - AZD6140 45 mg bd</title>
            <description>AZD6140 45 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>AZD6140 90 mg bd</title>
            <description>AZD6140 90 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Clopidogrel 75 mg od</title>
            <description>Clopidogrel 75 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>IPA Final Extent at 12 Hours Post Dose on Week 4 in Japanese Patients</title>
          <description>Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation:
Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval [0,100]; any data falling outside this range was truncated to the appropriate limit.</description>
          <population>Only Japanese participants who had IPA data at Week 4 were considered in this analysis. Arm AZD6140 90 mg bd includes one non-Japanese participant resident in Japan</population>
          <units>percentage inhibition</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.9" spread="20.9"/>
                    <measurement group_id="O2" value="66.8" spread="20.1"/>
                    <measurement group_id="O3" value="41.8" spread="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>IPA Final Extent at 24 Hours Post Dose on Week 4 in Japanese Patients</title>
        <description>Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation:
Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval [0,100]; any data falling outside this range was truncated to the appropriate limit.</description>
        <time_frame>Week 4</time_frame>
        <population>Only Japanese participants who had IPA data at Week 4 were considered in this analysis. Arm AZD6140 90 mg bd includes one non-Japanese participant resident in Japan</population>
        <group_list>
          <group group_id="O1">
            <title>AZD6140 45 mg bd</title>
            <description>AZD6140 45 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>AZD6140 90 mg bd</title>
            <description>AZD6140 90 mg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Clopidogrel 75 mg od</title>
            <description>Clopidogrel 75 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>IPA Final Extent at 24 Hours Post Dose on Week 4 in Japanese Patients</title>
          <description>Final extent IPA from pre-dose baseline was calculated using the following formula for ADP-induced platelet aggregation:
Percentage Inhibition = 100% x (PAs - PA) / (PAs) PA was the mean response at the given post dose time point and PAs was the mean response at pre dose baseline. Percentage inhibition was restricted to the closed interval [0,100]; any data falling outside this range was truncated to the appropriate limit.</description>
          <population>Only Japanese participants who had IPA data at Week 4 were considered in this analysis. Arm AZD6140 90 mg bd includes one non-Japanese participant resident in Japan</population>
          <units>percentage inhibition</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2" spread="23.3"/>
                    <measurement group_id="O2" value="59.1" spread="20.3"/>
                    <measurement group_id="O3" value="38.0" spread="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AZD6140 (Cmax) at Week 4</title>
        <description>Maximum plasma AZD6140 concentration</description>
        <time_frame>Week 4</time_frame>
        <population>Only Japanese participants who had IPA data at Week 4 were considered in this analysis</population>
        <group_list>
          <group group_id="O1">
            <title>AZD6140 45 mg bd in Japanese Patients</title>
            <description>AZD6140 45 mg twice daily in Japanese patients</description>
          </group>
          <group group_id="O2">
            <title>AZD6140 45 mg bd in Non-Japanese Patients</title>
            <description>AZD6140 45 mg twice daily in non-Japanese patients</description>
          </group>
          <group group_id="O3">
            <title>AZD6140 90 mg bd in Japanese Patients</title>
            <description>AZD6140 90 mg twice daily in Japanese patients</description>
          </group>
          <group group_id="O4">
            <title>AZD6140 90 mg bd in Non-Japanese Patients</title>
            <description>AZD6140 90 mg twice daily in non-Japanese patients</description>
          </group>
        </group_list>
        <measure>
          <title>AZD6140 (Cmax) at Week 4</title>
          <description>Maximum plasma AZD6140 concentration</description>
          <population>Only Japanese participants who had IPA data at Week 4 were considered in this analysis</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="422" spread="230"/>
                    <measurement group_id="O2" value="341" spread="370"/>
                    <measurement group_id="O3" value="931" spread="442"/>
                    <measurement group_id="O4" value="1380" spread="343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AZD6140 (AUC0-tau) at Week 4</title>
        <description>Area under the plasma concentration curve of AZD6140 from time zero to dosing interval</description>
        <time_frame>Week 4</time_frame>
        <population>In total 7 Japanese patients (4 patients in 45 mg and 3 patients in 90 mg) were excluded from the PK analysis set since PK samples of these patients were discarded due to a database set-up issue at the central laboratory.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD6140 45 mg bd in Japanese Patients</title>
            <description>AZD6140 45 mg twice daily in Japanese patients</description>
          </group>
          <group group_id="O2">
            <title>AZD6140 45 mg bd in Non-Japanese Patients</title>
            <description>AZD6140 90 mg twice daily in non-Japanese patients</description>
          </group>
          <group group_id="O3">
            <title>AZD6140 90 mg bd in Japanese Patients</title>
            <description>AZD6140 90 mg twice daily in Japanese patients</description>
          </group>
          <group group_id="O4">
            <title>AZD6140 90 mg bd in Non-Japanese Patients</title>
            <description>AZD6140 45 mg twice daily in non-Japanese patients</description>
          </group>
        </group_list>
        <measure>
          <title>AZD6140 (AUC0-tau) at Week 4</title>
          <description>Area under the plasma concentration curve of AZD6140 from time zero to dosing interval</description>
          <population>In total 7 Japanese patients (4 patients in 45 mg and 3 patients in 90 mg) were excluded from the PK analysis set since PK samples of these patients were discarded due to a database set-up issue at the central laboratory.</population>
          <units>ng.h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3050" spread="1940"/>
                    <measurement group_id="O2" value="2930" spread="3740"/>
                    <measurement group_id="O3" value="6080" spread="2600"/>
                    <measurement group_id="O4" value="10900" spread="2790"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AZD6140 (Tmax) at Week 4</title>
        <description>Time to reach peak or maximum concentration of AZD6140 following AZD6140 administration</description>
        <time_frame>Week 4</time_frame>
        <population>In total 7 Japanese patients (4 patients in 45 mg and 3 patients in 90 mg) were excluded from the PK analysis set since PK samples of these patients were discarded due to a database set-up issue at the central laboratory.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD6140 45 mg bd in Japanese Patients</title>
            <description>AZD6140 45 mg twice daily in Japanese patients</description>
          </group>
          <group group_id="O2">
            <title>AZD6140 45 mg bd in Non-Japanese Patients</title>
            <description>AZD6140 45 mg twice daily in non-Japanese patients</description>
          </group>
          <group group_id="O3">
            <title>AZD6140 90 mg bd in Japanese Patients</title>
            <description>AZD6140 90 mg twice daily in Japanese patients</description>
          </group>
          <group group_id="O4">
            <title>AZD6140 90 mg bd in Non-Japanese Patients</title>
            <description>AZD6140 90 mg twice daily in non-Japanese patients</description>
          </group>
        </group_list>
        <measure>
          <title>AZD6140 (Tmax) at Week 4</title>
          <description>Time to reach peak or maximum concentration of AZD6140 following AZD6140 administration</description>
          <population>In total 7 Japanese patients (4 patients in 45 mg and 3 patients in 90 mg) were excluded from the PK analysis set since PK samples of these patients were discarded due to a database set-up issue at the central laboratory.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" lower_limit="1.9" upper_limit="4.0"/>
                    <measurement group_id="O2" value="4.0" lower_limit="2.0" upper_limit="4.0"/>
                    <measurement group_id="O3" value="2.0" lower_limit="1.9" upper_limit="4.1"/>
                    <measurement group_id="O4" value="4.0" lower_limit="2.0" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AR-C124910XX (Cmax) at Week 4</title>
        <description>Maximum plasma concentration of AZD6140 drug metabolite AR-C124910XX</description>
        <time_frame>Week 4</time_frame>
        <population>In total 7 Japanese patients (4 patients in 45 mg and 3 patients in 90 mg) were excluded from the PK analysis set since PK samples of these patients were discarded due to a database set-up issue at the central laboratory.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD6140 45 mg bd in Japanese Patients</title>
            <description>AZD6140 45 mg twice daily in Japanese patients</description>
          </group>
          <group group_id="O2">
            <title>AZD6140 45mg bd in Non-Jpanese Patients</title>
            <description>AZD6140 45 mg twice daily in non-Japanese patients</description>
          </group>
          <group group_id="O3">
            <title>AZD6140 90 mg bd in Japanese Patients</title>
            <description>AZD6140 90 mg twice daily in Japanese patients</description>
          </group>
          <group group_id="O4">
            <title>AZD6140 90 mg bd in Non-Jpanese Patients</title>
            <description>AZD6140 90 mg twice daily in non-Japanese patients</description>
          </group>
        </group_list>
        <measure>
          <title>AR-C124910XX (Cmax) at Week 4</title>
          <description>Maximum plasma concentration of AZD6140 drug metabolite AR-C124910XX</description>
          <population>In total 7 Japanese patients (4 patients in 45 mg and 3 patients in 90 mg) were excluded from the PK analysis set since PK samples of these patients were discarded due to a database set-up issue at the central laboratory.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135" spread="53.3"/>
                    <measurement group_id="O2" value="101" spread="72.4"/>
                    <measurement group_id="O3" value="326" spread="139"/>
                    <measurement group_id="O4" value="381" spread="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AR-C124910XX (AUC0-tau) at Week 4</title>
        <description>Area under the plasma concentration curve of AZD6140 drug metabolite AR-C124910XX from time zero to dosing interval</description>
        <time_frame>Week 4</time_frame>
        <population>In total 7 Japanese patients (4 patients in 45 mg and 3 patients in 90 mg) were excluded from the PK analysis set since PK samples of these patients were discarded due to a database set-up issue at the central laboratory.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD6140 45 mg bd in Japanese Patients</title>
            <description>AZD6140 45 mg twice daily in Japanese patients</description>
          </group>
          <group group_id="O2">
            <title>AZD6140 45 mg bd in Non-Japanese Patients</title>
            <description>AZD6140 45 mg twice daily in non-Japanese patients</description>
          </group>
          <group group_id="O3">
            <title>AZD6140 90 mg bd in Japanese Patients</title>
            <description>AZD6140 90 mg twice daily in Japanese patients</description>
          </group>
          <group group_id="O4">
            <title>AZD6140 90 mg bd in Non-Japanese Patients</title>
            <description>AZD6140 90 mg twice daily in non-Japanese patients</description>
          </group>
        </group_list>
        <measure>
          <title>AR-C124910XX (AUC0-tau) at Week 4</title>
          <description>Area under the plasma concentration curve of AZD6140 drug metabolite AR-C124910XX from time zero to dosing interval</description>
          <population>In total 7 Japanese patients (4 patients in 45 mg and 3 patients in 90 mg) were excluded from the PK analysis set since PK samples of these patients were discarded due to a database set-up issue at the central laboratory.</population>
          <units>ng.h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1180" spread="490"/>
                    <measurement group_id="O2" value="954" spread="741"/>
                    <measurement group_id="O3" value="2720" spread="915"/>
                    <measurement group_id="O4" value="3380" spread="1580"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AR-C124910XX (Tmax) at Week 4</title>
        <description>Time to reach peak or maximum concentration of AZD6140 drug metabolite AR-C124910XX following AZD6140 administration</description>
        <time_frame>Week 4</time_frame>
        <population>In total 7 Japanese patients (4 patients in 45 mg and 3 patients in 90 mg) were excluded from the PK analysis set since PK samples of these patients were discarded due to a database set-up issue at the central laboratory.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD6140 45 mg bd in Japanese Patients</title>
            <description>AZD6140 45 mg twice daily in Japanese Patients</description>
          </group>
          <group group_id="O2">
            <title>AZD6140 45 mg bd in Non-Japanese Patients</title>
            <description>AZD6140 45 mg twice daily in non-Japanese patients</description>
          </group>
          <group group_id="O3">
            <title>AZD6140 90 mg bd in Japanese Patients</title>
            <description>AZD6140 90 mg twice daily in Japanese Patients</description>
          </group>
          <group group_id="O4">
            <title>AZD6140 90 mg bd in Non-Japanese Patients</title>
            <description>AZD6140 90 mg twice daily in non-Japanese patients</description>
          </group>
        </group_list>
        <measure>
          <title>AR-C124910XX (Tmax) at Week 4</title>
          <description>Time to reach peak or maximum concentration of AZD6140 drug metabolite AR-C124910XX following AZD6140 administration</description>
          <population>In total 7 Japanese patients (4 patients in 45 mg and 3 patients in 90 mg) were excluded from the PK analysis set since PK samples of these patients were discarded due to a database set-up issue at the central laboratory.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="33"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="1.9" upper_limit="11.9"/>
                    <measurement group_id="O2" value="4.0" lower_limit="2.0" upper_limit="8.0"/>
                    <measurement group_id="O3" value="2.1" lower_limit="1.9" upper_limit="8.0"/>
                    <measurement group_id="O4" value="2.0" lower_limit="2.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AZD6140 45 mg bd</title>
          <description>AZD6140 45 mg twice daily</description>
        </group>
        <group group_id="E2">
          <title>AZD6140 90 mg bd</title>
          <description>AZD6140 90 mg twice daily</description>
        </group>
        <group group_id="E3">
          <title>Clopidogrel 75 mg od</title>
          <description>Clopidogrel 75 mg once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>LIP AND/OR ORAL CAVITYCANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage subcutaneous</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

